<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9778">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709305</url>
  </required_header>
  <id_info>
    <org_study_id>0431-313</org_study_id>
    <nct_id>NCT01709305</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313 AM1)</brief_title>
  <official_title>A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus (Phase IV; Protocol No. MK-0431-313-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus
      metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes
      Mellitus (T2DM) participants who require the addition of a third oral anti-hyperglycemic
      agent (OAHA) according to China Guideline for Type 2 Diabetes. The three co-primary
      hypotheses are that after 24 weeks of treatment in phase 2, the mean change from baseline in
      hemoglobin A1c (A1c) in participants receiving either (1)acarbose or (2)repaglinide or
      (3)gliclazide added to sitagliptin and metformin combination is non-inferior to that of
      participants receiving glimepiride added to sitagliptin and metformin combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants coming on study will be stabilized to a standardized metformin dose: this may
      take about 10 weeks, and then combination therapy with metformin + sitagliptin will begin
      during Phase 1 (Week 0 through Week 20).  If a participant is already on a stabilized
      metformin dose, they will start immediately on combination therapy with metformin +
      sitagliptin for 20 weeks (Phase 1).

      In Phase 2, participants who have failed to achieve adequate glycemic control (A1c ≥ 7% and
      ≤ 10% at Week 16 and fasting finger stick glucose ≥130 mg/dL and ≤280 mg/dL at Week 20) will
      be randomized to receive add-on therapy with glimepiride, repaglinide, acarbose, or
      gliclazide for 24 weeks (Week 20 through Week 44).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)</measure>
    <time_frame>Phase 2 Baseline (Week 20), Week 44</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)</measure>
    <time_frame>Phase 2 Baseline (Week 20), Week 44</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypoglycemia Events (Phase 2)</measure>
    <time_frame>From Week 20 through Week 44</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gastrointestinal Adverse Events (Phase 2)</measure>
    <time_frame>From Week 20 through Week 44</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">5500</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin + Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin + Repaglinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin + Acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin + Gliclazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily</description>
    <arm_group_label>Metformin + Sitagliptin + Glimepiride</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Repaglinide</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Acarbose</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Gliclazide</arm_group_label>
    <other_name>Fortamet®</other_name>
    <other_name>Glucophage®</other_name>
    <other_name>Glucophage® XR</other_name>
    <other_name>Glumetza®</other_name>
    <other_name>Riomet®</other_name>
    <other_name>Metgluco®</other_name>
    <other_name>Glycoran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin, 100 mg oral tablet, once daily (QD)</description>
    <arm_group_label>Metformin + Sitagliptin + Glimepiride</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Repaglinide</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Acarbose</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin + Gliclazide</arm_group_label>
    <other_name>Januvia®</other_name>
    <other_name>Tesavel®</other_name>
    <other_name>Xelevia®</other_name>
    <other_name>Ristaben®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Acarbose, 50 mg oral tablets, TID (150 mg total daily dose)</description>
    <arm_group_label>Metformin + Sitagliptin + Acarbose</arm_group_label>
    <other_name>Precose®</other_name>
    <other_name>Glucobay™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily)</description>
    <arm_group_label>Metformin + Sitagliptin + Repaglinide</arm_group_label>
    <other_name>Prandin®</other_name>
    <other_name>Fulaidi™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily)</description>
    <arm_group_label>Metformin + Sitagliptin + Glimepiride</arm_group_label>
    <other_name>Amaryl®</other_name>
    <other_name>Glimy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose)</description>
    <arm_group_label>Metformin + Sitagliptin + Gliclazide</arm_group_label>
    <other_name>Diamicron MR™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has Type 2 Diabetes Mellitus

          -  Agrees to use an effective method of contraception or must not otherwise be at risk
             of becoming pregnant (female participants)

        Exclusion Criteria:

          -  Has a history of type 1 diabetes mellitus or a history of ketoacidosis

          -  Has been treated with insulin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a
             Glucagon-like peptide-1 (GLP-1) mimetic or analogue before

          -  Is on a weight loss program (not in maintenance phase), has started a weight loss
             medication, or has undergone bariatric surgery within 12 months

          -  Has undergone a surgical procedure within 4 weeks

          -  Has had new or worsening signs or symptoms of coronary heart disease

        or congestive heart failure within past 3 months, or has acute coronary syndrome, coronary
        artery intervention, or stroke or transient ischemic neurological disorder

          -  Has a medical history of active liver disease, including chronic active hepatitis B
             or C, primary biliary cirrhosis, or symptomatic gallbladder disease

          -  Has poorly controlled hypertension

          -  Has severe peripheral vascular disease

          -  Has human immunodeficiency virus (HIV)

          -  Has had a clinically important hematological disorder

          -  Routinely consumes &gt;2 alcoholic drinks per day or &gt;14 alcoholic drinks

        per week, or engages in binge drinking.

          -  Has a history of intolerance or hypersensitivity or any contraindication to

        study medications (including sitagliptin, metformin, glimepiride, repaglinide,

        acarbose or gliclazide) based upon the Chinese label

          -  Is on or likely to require treatment with ≥2 consecutive weeks or

        repeated courses of pharmacologic doses of corticosteroids (other than inhaled, nasal, or
        topical corticosteroids)

          -  Is pregnant or breast feeding or is expecting to conceive or donate eggs

        during the study, including 14 days following the last dose of study drug (female
        participants)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
